This review summarizes the health burden of human babesiosis emerging on a global scale. Authors discuss tools used to monitor the frequency and location of disease as well as demographics, modes of transmission and the location of human babesiosis. Authors further describe the causative Babesia spp. in North and South America, Europe, Asia, Africa, and Australia and present the primary symptomology and clinical features associated with infections.
The disease burden of human babesiosis is especially impactful on immunocompromised patients and the elderly population. Authors state that case numbers are greatly underestimated and are likely to increase, and they suggest that there is a need for improved surveillance, development of new antibiotics, supportive therapies, and a vaccine to limit the impact of the disease worldwide.
Read full text article here
Read additional LDA articles on Babesia here